Risk factors for predicting severe leukopenia induced by docetaxel plus prednisolone in patients with castration-resistant prostate cancer - Abstract

The purpose of this study was to extract the risk factors for GradeB3 leukopenia induced by docetaxel plus prednisolone (DP)therapy administered to patients with castration-resistant prostate cancer.

Rates of 59% for GradeB3 leukopenia and 11% for FN were observed. On multivariate analysis, the pretreatment white blood cell count(OR=0.502, 95%CI: 0.292- 0.862, p=0.01)was significantly associated with severe leukopenia induced by DP therapy. In addition, on univariate analysis, the pretreatment platelet count, disease extent, and bilirubin level were significant factors. We consider it necessary to immediately treat patients with these risks with G-CSF.

Written by:
Takada S, Tamaki S, Nagamori S, Endou M.   Are you the author?
Dept. of Pharmacy, National Hospital Organization Hokkaido Cancer Center.

Reference: Gan To Kagaku Ryoho. 2015 May;42(5):591-4.

PubMed Abstract
PMID: 25981653

UroToday.com Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.